CT Antigen TCR-redirected T Cells for Ovarian Cancer.

This is an open label clinical trial. Patients with the HLA-A201, HLA-A205, and/or HLA-A206
allele and whose tumor expresses the NY-ESO-1 tumor antigen will be eligible to receive
NY-ESO-1ᶜ²⁵⁹T. The trial is conducted entirely with outpatient procedures; however, patients
may be hospitalized for the cytoreductive chemotherapy at the discretion of the investigator.
Upon enrollment, patients will undergo leukapheresis for T cell collection, and their cells
will be genetically engineered and expanded ex vivo. Seven days prior to receiving T-cells
patients will undergo a cyclophosphamide conditioning regimen to potentiate the
immunotherapy. The cell product will be infused as a single infusion (Day 0, typically
Monday) to mitigate risks associated with unanticipated infusion reactions. Patients will be
followed daily for the first week, weekly until 4 weeks, 8 weeks, and 12 weeks and then at 6
months and every 3 months until disease progression. Patients will undergo disease monitoring
by MRI/CT scan (as appropriate for disease) at baseline, day 28, 8 weeks and 12 weeks, and
months 6, and every 3 months until progression. Tumor biopsies will be taken at baseline,
Week 8, and upon progression. In patients who have progressive disease following initial
infusion but whose tumors continue to express NY-ESO-1, these patients may be eligible for a
second infusion with redirected T cells. At disease progression, the interventional portion
of the protocol ends and long term follow-up (LTFU) begins, in accordance with FDA
regulations. LTFU occurs semiannually for up to 5 years post infusion and then annually
thereafter for up to 15 years.

Inclusion Criteria:

- Must have a diagnosis of recurrent epithelial ovarian, primary peritoneal or fallopian
tube carcinoma with refractory or platinum resistant disease and/or have received ≥ 2
lines of chemotherapy

- Age ≥ 18 years of age

- No significant immunodeficiency

- Have been informed of other treatment options

- Must be HLA A*0201, HLA-A*0205, and/or HLA-A*0206 positive by high resolution testing.

- Patient's tumor must be positive by histological assay for NY-ESO-1ᶜ²⁵⁹T, according to
the screening algorithm as described in Section 3.3.1. Positive expression is defined
as ≥ 50% of cells that are 2+ and/or 3+ by immunohistochemistry

- ECOG performance status of 0 or 1

- Life expectancy of > 4 months

- Prior therapies:

1. prior immunotherapy, or prior investigational agents should be washed out 4 weeks
before apheresis and must be completed 4 weeks prior to pre-infusion
lymphodepletive chemotherapy.

2. monoclonal antibody therapy must be completed at least 6 weeks prior to
pre-infusion lymphodepletive chemotherapy

3. All previous cytotoxic chemotherapy, monoclonal antibody therapy, immune therapy
should be washed out 3 weeks before apheresis and must be completed at least 3
weeks prior to pre-infusion lymphodepletive chemotherapy.

4. Systemic corticosteroid or other immunosuppressive therapy should be washed out 2
weeks before apheresis and must be completed at least 2 weeks prior to
pre-infusion lymphodepletive chemotherapy

5. Biologic or other approved molecular targeted small molecule inhibitors should be
washed out 1 week before apheresis and must be completed at least 1 week prior to
pre-infusion lymphodepletive chemotherapy.

6. Any grade 3 or 4 -hematologic toxicity of previous therapy must have resolved to
grade 2 or less prior to apheresis and any grade 3 or 4 toxicity must have
resolved to grade 2 or less prior to pre-infusion lymphodepletive chemotherapy.

- Must have measurable disease as defined by RECIST 1.1.

- Must have adequate venous access for apheresis.

- Women of childbearing potential are requested to use acceptable methods of birth
control for the duration of the study and until persistence of the study drug is no
longer detected in the patient. This may be a period of several years. Methods for
acceptable birth control include: condoms, diaphragm or cervical cap with spermicide,
intrauterine device, and hormonal contraception. It is recommended that a combination
of two methods be used.

Patients must have normal organ and marrow function as defined below:

- Leukocytes ≥ 3,000/mcL

- Absolute Neutrophil Count ≥ 1,500/mcL

- Platelets ≥ 100,000/mcL

- Total bilirubin ≤ 1.5 ULN

- AST(SGOT)/ALT(SGPT) ≤ 2.5 X institutional upper limit of normal

- creatinine ≤ 2.0 mg/dL OR

- creatinine clearance > 60 mL/min for patients with creatinine levels above
institutional normal

- Patient must understand the investigational nature of this study and sign an
Independent Ethics Committee/Institutional Review Board approved written informed
consent form prior to receiving any study related procedure.

Exclusion Criteria:

- Currently receiving any other investigational agents

- Patients with active brain metastases. Patients with prior history of brain metastasis
who have undergone local therapy (i.e. metastatectomy and/or radiation) and show no
evidence of local recurrence or progression over the past 6 months are eligible

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to cyclophosphamide or other agents used in the study

- Prior malignancy (except non-melanoma skin cancer) within 18 months of study entry
NOTE: Patients must be in complete remission from prior malignancy in order to be
eligible to enter the study.

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

- Use of chronic corticosteroids, hydroxyurea, or immunomodulating agents (e.g.
interleukin-2, interferon-alpha or gamma, granulocyte colony stimulating factors,
etc.) within 30 days prior to study entry. NOTE: Recent or current use of inhaled
steroids is not exclusionary. If subjects are prescribed a brief course of oral
corticosteroids, the use should be limited to less than 7 days. Use of steroids before
apheresis and immune assessment blood draws should be discouraged as it will affect
white blood cell function.

- Active infection with HIV, HBV or HCV

- Receipt of an experimental vaccine within 2 months or in the opinion of the
Investigator is responding to an experimental vaccine given within 6 months, or has
received any previous gene therapy using an integrating vector

- History of severe autoimmune disease requiring steroids or other immunosuppressive
treatments

- Lack of availability of a patient for immunological and clinical follow-up assessment

- Evidence or history of significant cardiac disease